From the Editor ’s Desk…
It has not been well established if patients with autoimmune hepatitis (AIH) treated with immunosuppressive drugs are at higher risk of severe COVID-19 infection. The current study by Marjot and coworkers reports the course of SARS CoV-2 infection in 70 patients with AIH on immunosuppressive therapy and compares it with that of 862 patients with non-AIH chronic liver disease (CLD), all from 3 international large-scale reporting registries, and also with 769 consecutive non-CLD controls. There were no differences between AIH and non-AIH CLD patients for rate of hospitalisation, intensive care unit requirement, invasive ventilation or death.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli Tags: From the Editor's Desk Source Type: research
More News: Autoimmune Disease | COVID-19 | Gastroenterology | Hepatitis | Intensive Care | Liver | Liver Disease | SARS | Study | Urology & Nephrology